Edition:
India

Medtronic PLC (MDT.N)

MDT.N on New York Stock Exchange

80.39USD
23 Feb 2018
Change (% chg)

$-0.02 (-0.02%)
Prev Close
$80.41
Open
$80.95
Day's High
$81.20
Day's Low
$79.89
Volume
1,098,408
Avg. Vol
1,373,271
52-wk High
$89.71
52-wk Low
$76.52

Select another date:

Tue, Feb 20 2018

Medtronic quarterly revenue beats, margins disappoint

Medical device maker Medtronic Plc's quarterly revenue beat analysts' expectations as new product launches drove sales across its business units, but weaker-than-expected margins clouded the earnings report.

UPDATE 2-Medtronic quarterly revenue beats, margins disappoint

Feb 20 Medical device maker Medtronic Plc's quarterly revenue beat analysts' expectations as new product launches drove sales across its business units, but weaker-than-expected margins clouded the earnings report.

BRIEF-Medtronic Q3 GAAP Loss Per Share $1.03

* ‍RTG WORLDWIDE Q3 REVENUE OF $1.944 BILLION INCREASED 7 PERCENT, OR 5 PERCENT ON A CONSTANT CURRENCY BASIS​

Medtronic posts loss due to $2.2 bln U.S. tax law charge

Feb 20 Medtronic Plc reported a third-quarter loss on Tuesday, compared with a year-ago profit, hurt by a $2.2 billion charge related to recent changes in U.S. tax laws.

UPDATE 3-Cardinal Health profit beats on CVS tie-up, Medtronic unit buy

* Shares up nearly 5 pct (Adds comments from conference call, analyst comments, background, share movement)

BRIEF-Medtronic And Philips Partner To Innovate In Lung Cancer Management

* MEDTRONIC AND PHILIPS PARTNER TO INNOVATE IN LUNG CANCER MANAGEMENT

BRIEF-Medtronic Launches Enchant Study To Evaluate Chevar Parallel Graft Technique With The Endurant II/IIs Stent Graft System

* MEDTRONIC LAUNCHES ENCHANT STUDY TO EVALUATE CHEVAR PARALLEL GRAFT TECHNIQUE WITH THE ENDURANT II/IIS STENT GRAFT SYSTEM Source text for Eikon: Further company coverage:

BRIEF-Medtronic Receives FDA Clearance For Riptide Aspiration System

* MEDTRONIC RECEIVES FDA CLEARANCE FOR RIPTIDE(TM) ASPIRATION SYSTEM

BRIEF-FDA Approves Innovative Clinician Programmer For The Medtronic Synchromed II Intrathecal Drug Delivery System

* FDA APPROVES INNOVATIVE CLINICIAN PROGRAMMER FOR THE MEDTRONIC SYNCHROMED II INTRATHECAL DRUG DELIVERY SYSTEM FOR CHRONIC PAIN AND SEVERE SPASTICITY Source text for Eikon: Further company coverage:

Medtronic unveils restructuring plan

Medtronic Plc on Monday unveiled a restructuring plan that it expects will help it save $500 million to $700 million annually over the next five years.

Select another date: